Hayakawa M - Search Results

1

Republication: Targeting PI3KC2β Impairs Proliferation and Survival in Acute Leukemia, Brain Tumours and Neuroendocrine Tumours.

Boller D, Doepfner KT, Laurentiis A, Guerreiro AS, Marinov M, Shalaby T, Depledge P, Robson A, Saghir N, Hayakawa M, Kaizawa H, Koizumi T, Ohishi T, Fattet S, Delattre O, Schweri-Olac A, Höland K, Grotzer MA, Frei K, Spertini O, Waterfield MD, Arcaro A. Boller D, et al. Among authors: hayakawa m. Anticancer Res. 2022 Jun;42(6):3217-3230. doi: 10.21873/anticanres.15812. Anticancer Res. 2022. PMID: 35641277 Free article.

2

Targeting PI3KC2β impairs proliferation and survival in acute leukemia, brain tumours and neuroendocrine tumours.

Boller D, Doepfner KT, De Laurentiis A, Guerreiro AS, Marinov M, Shalaby T, Depledge P, Robson A, Saghir N, Hayakawa M, Kaizawa H, Koizumi T, Ohishi T, Fattet S, Delattre O, Schweri-Olac A, Höland K, Grotzer MA, Frei K, Spertini O, Waterfield MD, Arcaro A. Boller D, et al. Among authors: hayakawa m. Anticancer Res. 2012 Aug;32(8):3015-27. Anticancer Res. 2012. PMID: 22843869 Retracted.

3

Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110alpha inhibitors.

Hayakawa M, Kawaguchi K, Kaizawa H, Koizumi T, Ohishi T, Yamano M, Okada M, Ohta M, Tsukamoto S, Raynaud FI, Parker P, Workman P, Waterfield MD. Hayakawa M, et al. Bioorg Med Chem. 2007 Sep 1;15(17):5837-44. doi: 10.1016/j.bmc.2007.05.070. Epub 2007 Jun 6. Bioorg Med Chem. 2007. PMID: 17601739

4

Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110alpha inhibitors.

Hayakawa M, Kaizawa H, Moritomo H, Koizumi T, Ohishi T, Okada M, Ohta M, Tsukamoto S, Parker P, Workman P, Waterfield M. Hayakawa M, et al. Bioorg Med Chem. 2006 Oct 15;14(20):6847-58. doi: 10.1016/j.bmc.2006.06.046. Epub 2006 Jul 11. Bioorg Med Chem. 2006. PMID: 16837202

5

Synthesis and biological evaluation of imidazo[1,2-a]pyridine derivatives as novel PI3 kinase p110alpha inhibitors.

Hayakawa M, Kaizawa H, Kawaguchi K, Ishikawa N, Koizumi T, Ohishi T, Yamano M, Okada M, Ohta M, Tsukamoto S, Raynaud FI, Waterfield MD, Parker P, Workman P. Hayakawa M, et al. Bioorg Med Chem. 2007 Jan 1;15(1):403-12. doi: 10.1016/j.bmc.2006.09.047. Epub 2006 Oct 16. Bioorg Med Chem. 2007. PMID: 17049248

6

Synthesis and biological evaluation of pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as novel PI3 kinase p110alpha inhibitors.

Hayakawa M, Kaizawa H, Moritomo H, Koizumi T, Ohishi T, Yamano M, Okada M, Ohta M, Tsukamoto S, Raynaud FI, Workman P, Waterfield MD, Parker P. Hayakawa M, et al. Bioorg Med Chem Lett. 2007 May 1;17(9):2438-42. doi: 10.1016/j.bmcl.2007.02.032. Epub 2007 Feb 15. Bioorg Med Chem Lett. 2007. PMID: 17339109

7

Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases.

Raynaud FI, Eccles S, Clarke PA, Hayes A, Nutley B, Alix S, Henley A, Di-Stefano F, Ahmad Z, Guillard S, Bjerke LM, Kelland L, Valenti M, Patterson L, Gowan S, de Haven Brandon A, Hayakawa M, Kaizawa H, Koizumi T, Ohishi T, Patel S, Saghir N, Parker P, Waterfield M, Workman P. Raynaud FI, et al. Among authors: hayakawa m. Cancer Res. 2007 Jun 15;67(12):5840-50. doi: 10.1158/0008-5472.CAN-06-4615. Cancer Res. 2007. PMID: 17575152 Free article.

8

A selective PIKfyve inhibitor blocks PtdIns(3,5)P(2) production and disrupts endomembrane transport and retroviral budding.

Jefferies HB, Cooke FT, Jat P, Boucheron C, Koizumi T, Hayakawa M, Kaizawa H, Ohishi T, Workman P, Waterfield MD, Parker PJ. Jefferies HB, et al. Among authors: hayakawa m. EMBO Rep. 2008 Feb;9(2):164-70. doi: 10.1038/sj.embor.7401155. Epub 2008 Jan 11. EMBO Rep. 2008. PMID: 18188180 Free PMC article.

9

PIKfyve negatively regulates exocytosis in neurosecretory cells.

Osborne SL, Wen PJ, Boucheron C, Nguyen HN, Hayakawa M, Kaizawa H, Parker PJ, Vitale N, Meunier FA. Osborne SL, et al. Among authors: hayakawa m. J Biol Chem. 2008 Feb 1;283(5):2804-13. doi: 10.1074/jbc.M704856200. Epub 2007 Nov 26. J Biol Chem. 2008. PMID: 18039667 Free article.

10

Pharmacological profile of ASP8497, a novel, selective, and competitive dipeptidyl peptidase-IV inhibitor, in vitro and in vivo.

Someya Y, Tahara A, Nakano R, Matsuyama-Yokono A, Nagase I, Fukunaga Y, Takasu T, Hayakawa M, Shibasaki M. Someya Y, et al. Among authors: hayakawa m. Naunyn Schmiedebergs Arch Pharmacol. 2008 May;377(3):209-17. doi: 10.1007/s00210-008-0277-8. Epub 2008 Apr 9. Naunyn Schmiedebergs Arch Pharmacol. 2008. PMID: 18398600

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,713 results

Search Page